Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
Brief Summary: Background/Aims:

The investigators explored the therapeutic effects of probiotics in patients with AH.

Methods:

Between September 2010 and April 2012, the investigators conducted a 7-day, double-controlled, randomized, prospective clinical trial comparing the efficacy of probiotics in improving liver enzymes, LPS, pro-inflammatory cytokines. AH was defined as an aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2 and elevated AST (ALT) level with an alcohol consumption history within 48 hours. Patients were randomized to receive 7 days of probiotics (1500 mg/day) or placebo. The levels of liver enzymes, modified Discriminant Function (mDF), LPS, and pro-inflammatory cytokines were checked at baseline and again after therapy.


Options:
A: Arm Label: Diet advices; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Optimal Diet | Arm Label: Diet advices + VSL-3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: VSL#3® probiotic blend | Arm Label: Diet advices + 5203-L; Type: EXPERIMENTAL; Interventions: Dietary Supplement: AISA-5203-L fruit extracted terpene | Arm Label: Diet advices + Argan oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Argan oil | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3® probiotic blend; Assigned to Arm(s): Diet advices + VSL-3 | Intervention Type: DIETARY_SUPPLEMENT; Name: AISA-5203-L fruit extracted terpene; Assigned to Arm(s): Diet advices + 5203-L | Intervention Type: DIETARY_SUPPLEMENT; Name: Argan oil; Assigned to Arm(s): Diet advices + Argan oil | Intervention Type: BEHAVIORAL; Name: Optimal Diet; Assigned to Arm(s): Diet advices
B: Arm Label: Rifaximin; Type: EXPERIMENTAL; Interventions: Drug: Rifaximin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rifaximin; Assigned to Arm(s): Rifaximin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Optimal Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Optimal Diet | Arm Label: VSL#3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: VSL#3® | Arm Label: AISA-5203-L; Type: EXPERIMENTAL; Interventions: Dietary Supplement: AISA-5203-L | Arm Label: Argan oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Argan oil | Intervention Type: BEHAVIORAL; Name: Optimal Diet; Assigned to Arm(s): Optimal Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3®; Assigned to Arm(s): VSL#3 | Intervention Type: DIETARY_SUPPLEMENT; Name: AISA-5203-L; Assigned to Arm(s): AISA-5203-L | Intervention Type: DIETARY_SUPPLEMENT; Name: Argan oil; Assigned to Arm(s): Argan oil
D: Arm Label: alcohol, hepatitis, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: alcohol, hepatitis, Placebo | Arm Label: hepatitis, alcohol, probiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: hepatitis, alcohol, probiotics | Intervention Type: DRUG; Name: hepatitis, alcohol, probiotics; Assigned to Arm(s): hepatitis, alcohol, probiotics | Intervention Type: DRUG; Name: alcohol, hepatitis, Placebo; Assigned to Arm(s): alcohol, hepatitis, Placebo

Answer: D